New family of molecules with oral therapeutic potential in obesity, hepatic steatosis, NASH, hypertension, dyslipidemia and type 2 diabetes

Exceptional Innovationon Diabetes

Innovation on metabolic syndrome

  • Reduction of obesity by 15% of body weight and more than 50% of excess weight.
  • Important reduction in hepatic steatosis and NASH.
  • Glucose regulatory activity by insulin sensitization
  • Proved regulating effect in diabetes, hypertension, dyslipidemia, overweight, hepatic steatosis and NASH.
  • No detectable toxicity in animal models
Additional Information

Additional Information

  • Positive cardiovascular effects by reducing systolic arterial pressure and dyslipidemia.
  • Simple method of synthesis with high yield and purity.
  • Efficacy comparable to reference antidiabetics (metformin, pioglitazone)
  • Worldwide patent protection

Company

Biotechnology company supported by a prestigious multidisciplinary team, CROs, and universities operating from several continents.

More information

Scientific Development

Family of molecules in preclinical development with proven therapeutic potential in animal models by prestigious CROs.

More information

Patents

All our compounds are protected by international patent, with national phases granted in the main countries of the world.

More information

Scientific presentation of our main compound SJT4a

New family of molecules with oral therapeutic potential in obesity, hepatic steatosis, NASH, hypertension, dyslipidemia and type 2 diabetes